Kodiak Sciences Inc.(KOD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KOD Kodiak Sciences Inc.

休市中 10-23 16:00:00 EDT

87.63

+1.85

+2.16%

盘后87.63

+0.000.00%

19:36 EDT

最高87.85	最低83.16	成交量52.69万
今开85.13	昨收85.78	日振幅5.47%
总市值54.84亿	流通市值32.42亿	总股本6,258万
成交额4,561万	换手率1.42%	流通股本3,699万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":87.63,"timestamp":1792785600000,"preClose":85.78,"halted":0,"volume":526946,"hourTrading":{"tag":"盘后","latestPrice":87.63,"preClose":87.63,"latestTime":"19:36 EDT","volume":6886,"amount":603423.51,"timestamp":1792798571201,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021566798787596108,"floatShares":36991100,"shares":62578441,"eps":-4.157111,"marketStatus":"休市中","change":1.85,"latestTime":"10-23 16:00:00 EDT","open":85.13,"high":87.85,"low":83.1567,"amount":45611278.574609995,"amplitude":0.054713,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.157111,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":85.78,"preHourTrading":{"tag":"盘前","latestPrice":85.01,"preClose":85.78,"latestTime":"09:29 EDT","volume":187,"amount":15950.219229999999,"timestamp":1792762199941,"change":-0.77,"changeRate":-0.008976,"amplitude":0.045349},"postHourTrading":{"tag":"盘后","latestPrice":87.63,"preClose":87.63,"latestTime":"19:36 EDT","volume":6886,"amount":603423.51,"timestamp":1792798571201,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5756741704064521,"impliedVol":0.8271,"impliedVolPercentile":0.1394},"requestUrl":"/m/hq/s/KOD","defaultTab":"news","newsList":[{"id":"1133467830","title":"异动解读｜Kodiak Sciences盘中下跌5.01%，眼科三期进展与董事增持催化持续交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1133467830","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133467830?lang=zh_cn&edition=full","pubTime":"2026-10-22 02:51","pubTimestamp":1792608663,"startTime":"0","endTime":"0","summary":"10月22日，Kodiak Sciences盘中下跌5.01%，报88.315美元/股，成交额5527.13万美元。公开消息面上，市场仍在交易公司眼科项目三期积极进展及董事Felix Baker大额增持的后续影响，但股价当日出现回落。此前公司披露，Zenkuda和tabirafusp-ted在湿性AMD三期研究中达到主要终点，且计划于第四季度递交部分眼科项目数据。随后Felix Baker通过Baker Bros. Advisors买入约1.57亿美元股份，成交价约80.85美元，相关机构持股升至约35%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"眼科三期进展催化，Kodiak股价回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194422235","title":"异动解读｜Kodiak Sciences盘中上涨5.11%，眼科三期积极进展与董事大额增持持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1194422235","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194422235?lang=zh_cn&edition=full","pubTime":"2026-10-20 23:30","pubTimestamp":1792510246,"startTime":"0","endTime":"0","summary":"10月20日，Kodiak Sciences盘中上涨5.11%，报96.02美元/股，成交额2746.88万美元。此次异动的公开催化仍集中在两方面：公司此前披露Zenkuda和tabirafusp-ted在湿性AMD三期研究中达到主要终点，且董事Felix Baker随后通过Baker Bros. Advisors买入约1.57亿美元股份。已披露信息显示，Baker本次买入价格约80.85美元，为其迄今最大单次增持，相关机构持股升至约35%；公司并计划于第四季度递交部分眼科项目数据，临床里程碑叠加大股东增持继续支撑市场关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"眼科三期告捷，大股东重金加仓","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140825932","title":"异动解读｜Kodiak Sciences夜盘上涨5.07%，眼科三期积极进展与董事大额增持持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1140825932","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140825932?lang=zh_cn&edition=full","pubTime":"2026-10-20 14:17","pubTimestamp":1792477032,"startTime":"0","endTime":"0","summary":"10月20日，Kodiak Sciences夜盘上涨5.07%，报95.98美元/股，成交额2124.73美元。此次异动的公开催化仍集中在两方面：公司此前披露Zenkuda和tabirafusp-ted在湿性AMD三期研究中达到主要终点，且董事Felix Baker随后通过Baker Bros. Advisors买入约1.57亿美元股份。已披露信息显示，Baker本次买入价格约80.85美元，为其迄今最大单次增持，相关机构持股升至约35%；公司并计划于第四季度递交部分眼科项目数据，临床里程碑叠加大股东增持继续支撑市场关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kodiak夜盘走高，眼科突破与大股东增持共振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163670743","title":"异动解读｜Kodiak Sciences盘中上涨6.27%，眼科三期积极进展与董事大额增持持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1163670743","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163670743?lang=zh_cn&edition=full","pubTime":"2026-10-20 00:13","pubTimestamp":1792426385,"startTime":"0","endTime":"0","summary":"10月20日，Kodiak Sciences盘中上涨6.27%，报91.13美元／股，成交额2324.53万美元。此次异动的公开催化仍集中在两方面：公司此前披露Zenkuda和tabirafusp-ted在湿性AMD三期研究中达到主要终点，且董事Felix Baker随后通过Baker Bros. Advisors买入约1.57亿美元股份。已披露信息显示，Baker本次买入价格约80.85美元，为其迄今最大单次增持，相关机构持股升至约35%；公司则计划于第四季度递交部分眼科项目数据。临床里程碑叠加大股东高位增持，持续支撑市场关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kodiak Sciences盘中大涨，眼科三期与大股东增持共振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189069171","title":"异动解读｜Kodiak Sciences Inc.盘中上涨5.2%，眼科三期积极进展与董事大额增持持续受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1189069171","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189069171?lang=zh_cn&edition=full","pubTime":"2026-10-16 00:32","pubTimestamp":1792081926,"startTime":"0","endTime":"0","summary":"10月16日，Kodiak Sciences Inc.盘中上涨5.2%，报85.31美元/股，成交额4618.32万美元。消息面上，公司此前披露两款眼科候选药在三期试验中达到主要终点，且董事Felix Baker于9月末通过Baker Bros. Advisors买入约1.57亿美元股份，市场仍在消化相关利好。公开信息显示，Baker此次买入价格约80.85美元，为其迄今最大单次增持，相关基金对Kodiak Sciences持股升至约35%。更早前，公司称Zenkuda和tabirafusp-ted在湿性年龄相关性黄斑变性三期研究中实现主要终点，并计划于第四季度向监管机构递交部分数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kodiak Sciences盘中上涨，眼科三期利好受关注","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183636536","title":"异动解读｜Kodiak Sciences Inc.盘中下跌5.6%，大额内幕增持效应边际降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1183636536","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183636536?lang=zh_cn&edition=full","pubTime":"2026-10-14 22:23","pubTimestamp":1791987781,"startTime":"0","endTime":"0","summary":"10月14日，Kodiak Sciences Inc.盘中下跌5.6%，报86.5美元/股，成交额2823.9万美元。近期可关联的公开消息是，公司董事Felix Baker于9月末通过Baker Bros. Advisors买入约1.57亿美元股份，增持价格约80.85美元，相关机构随后将其列为重点关注个股。披露显示，这笔交易为其迄今最大单次买入，相关基金对Kodiak Sciences持股升至约35%。更早前，公司两款眼科候选药在三期试验中达到主要终点，曾推动股价明显上行；当前回落显示前期利好交易的边际提振有所减弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak盘中下跌，内幕增持效应降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193074609","title":"异动解读｜Kodiak Sciences Inc.盘中下跌5.03%，大额内幕增持效应边际降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1193074609","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193074609?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:47","pubTimestamp":1791913635,"startTime":"0","endTime":"0","summary":"10月14日，Kodiak Sciences Inc.盘中下跌5.03%，报94.27美元／股，成交额6890.76万美元。近期可关联的公开消息是，公司董事Felix Baker于9月末通过Baker Bros. Advisors买入约1.57亿美元股份，增持价格约80.85美元，Smart Insider随后将其列为当周重点股票。披露显示，该笔交易为其迄今最大单次买入，相关基金对Kodiak Sciences持股升至约35%；更早前公司还公布两款眼科候选药在三期试验中达到主要终点，曾推动股价大幅上行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kodiak Sciences盘中下挫，大额增持效应降温","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100744830","title":"异动解读｜Kodiak Sciences盘中上涨5.63%，内部人增持强化市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1100744830","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100744830?lang=zh_cn&edition=full","pubTime":"2026-10-09 23:57","pubTimestamp":1791561424,"startTime":"0","endTime":"0","summary":"10月9日，Kodiak Sciences盘中上涨5.63%，报99.64美元/股，成交额4696.97万美元。消息面上，公司非执行董事Felix Baker于9月29日以每股80.85美元的价格通过关联基金Baker Bros. Advisors增持了1.57亿美元的股份，持股比例提升至35%。此前在9月28日，公司公布DAYBREAK III期试验中两款候选眼药Zenkuda与tabirafusp-ted均达到主要终点，股价单日上涨177.96%。这一重大临床里程碑叠加内部人大规模增持，形成基本面与信心面的双重驱动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大股东巨额增持，Kodiak盘中大涨","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127790909","title":"异动解读｜Kodiak Sciences盘中下跌5.09%，利好兑现压力显现","url":"https://stock-news.laohu8.com/highlight/detail?id=1127790909","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127790909?lang=zh_cn&edition=full","pubTime":"2026-10-05 22:19","pubTimestamp":1791209967,"startTime":"0","endTime":"0","summary":"10月5日，Kodiak Sciences盘中下跌5.09%，报89.65美元/股。基准研究/眼科学数据披露后获利盘回吐压力显现。Kodiak Sciences Inc.是一家临床阶段的生物制药公司，专门研究治疗慢性高流行性视网膜疾病的新疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"利好兑现后Kodiak回落，眼科新药热度降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124084461","title":"异动解读｜Kodiak Sciences盘中下跌5.08%，报93.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124084461","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124084461?lang=zh_cn&edition=full","pubTime":"2026-10-02 22:01","pubTimestamp":1790949663,"startTime":"0","endTime":"0","summary":"10月2日，Kodiak Sciences盘中下跌5.08%，报93.46美元/股，成交额3080.33万美元。Kodiak Sciences所在的生物科技行业中，个股中，Moderna涨0.13%，吉利德科学跌0.74%，艾伯维公司涨0.29%，安进跌0.31%，Natera涨0.24%。Kodiak Sciences Inc.是一家临床阶段的生物制药公司，专门研究治疗慢性高流行性视网膜疾病的新疗法，其最先进的候选产品使用公司抗体生物聚合物偶联平台构建，旨在维持眼组织中有效的药物水平。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118556380","title":"异动解读｜Kodiak Sciences盘中上涨6.9%，大股东Baker Brothers大幅增持逾35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1118556380","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118556380?lang=zh_cn&edition=full","pubTime":"2026-10-01 21:34","pubTimestamp":1790861684,"startTime":"0","endTime":"0","summary":"10月1日，Kodiak Sciences盘中上涨6.9%，报101.48美元/股，成交额2186.25万美元。消息面上，公司董事兼10%以上股东Felix J. Baker与Julian C. Baker通过旗下基金667, L.P.及Baker Brothers Life Sciences LP，于9月28日至29日在二级市场多次买入公司普通股，累计增持约35.9万股，成交均价区间约84至90美元，交易完成后两只基金合计持股约2019万股，进一步巩固大股东地位。此外，Felix J. Baker还另有多笔交易累计增持超86万股，价格区间覆盖60.50至86.47美元。公司计划于第四季度向监管机构提交相关数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kodiak大涨，大股东增持释放利好","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183108251","title":"Form 4 | Kodiak Sciences 股东兼董事 Baker Felix 与 Baker Julian 通过旗下基金合计增持约359,000股普通股（P）","url":"https://stock-news.laohu8.com/highlight/detail?id=1183108251","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183108251?lang=zh_cn&edition=full","pubTime":"2026-10-01 04:35","pubTimestamp":1790800516,"startTime":"0","endTime":"0","summary":"根据最新提交的Form 4，Felix J. Baker 与 Julian C. Baker 作为 Kodiak Sciences Inc.的董事及10%股东，通过旗下基金 667, L.P. 与 Baker Brothers Life Sciences LP 于2026年9月28日至29日多次在二级市场买入公司普通股，单笔交易数量从数百股至近20万股不等，成交均价区间约在84至90美元，累计增持约35.9万股。交易完成后，两只基金合计持股约2,019万股，进一步巩固其大股东地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146381561","title":"Kodiak Sciences Inc.董事 Felix J. Baker 增持227671股","url":"https://stock-news.laohu8.com/highlight/detail?id=1146381561","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146381561?lang=zh_cn&edition=full","pubTime":"2026-10-01 04:35","pubTimestamp":1790800516,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc.董事 Felix J. Baker 于2026年9月28日通过多项交易累计购入227,671股普通股。每股交易价格在79.07美元至86.47美元之间。Felix J. Baker是一位已知的活跃投资者，本次大规模增持可能表明他对公司未来前景的信心，并对市场起到积极的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122019945","title":"Kodiak Sciences Inc.董事Felix J. Baker增持639,386股","url":"https://stock-news.laohu8.com/highlight/detail?id=1122019945","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122019945?lang=zh_cn&edition=full","pubTime":"2026-10-01 04:30","pubTimestamp":1790800217,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc.董事Felix J. Baker于2026年9月28日通过多个交易共计增持了639,386股普通股。这些交易价格范围从60.50美元到78.91美元不等。随着持股比例的增加，此次增持可能表明该公司受到管理层的看好，这对市场可能是一个积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kodiak Sciences Inc.董事Felix J. Baker增持639,386股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103201498","title":"异动解读｜Kodiak Sciences盘中上涨6.48%，III期临床积极数据持续提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1103201498","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103201498?lang=zh_cn&edition=full","pubTime":"2026-09-30 21:34","pubTimestamp":1790775275,"startTime":"0","endTime":"0","summary":"9月30日，Kodiak Sciences盘中上涨6.48%，报96.805美元/股，成交额5448.19万美元。消息面上，公司此前宣布旗下两款实验性眼科药物Zenkuda及tabirafusp-ted在湿性年龄相关性黄斑变性III期临床试验中均达到主要终点，两项治疗在第一年视力改善方面均实现对阿柏西普的非劣效性，且54%的患者在第一年内维持了六个月的给药间隔。公司计划于第四季度向监管机构提交Zenkuda在五项III期研究中的数据，覆盖湿性黄斑变性、糖尿病视网膜病变及视网膜静脉阻塞后黄斑水肿等适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Kodiak Sciences盘中上涨，III期临床数据持续提振","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114345070","title":"异动解读｜Kodiak Sciences夜盘下跌7.83%，报82.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114345070","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114345070?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:09","pubTimestamp":1790644145,"startTime":"0","endTime":"0","summary":"9月29日，Kodiak Sciences夜盘下跌7.83%，报82.88美元/股，成交额45.17万美元。Kodiak Sciences所在的生物科技行业中，个股中，Moderna跌0.81%，安进涨0%，艾伯维公司涨0%，再生元制药公司涨0%，吉利德科学涨0%。Kodiak Sciences是一家临床阶段的生物制药公司，专门研究治疗慢性高流行性视网膜疾病的新疗法，其最先进的候选产品使用公司抗体生物聚合物偶联平台构建，旨在维持眼组织中有效的药物水平。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196770946","title":"异动解读｜Kodiak Sciences盘中上涨146.43%，两款眼科药物III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1196770946","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196770946?lang=zh_cn&edition=full","pubTime":"2026-09-28 23:02","pubTimestamp":1790607753,"startTime":"0","endTime":"0","summary":"9月28日，Kodiak Sciences盘中上涨146.43%，报79.72美元/股，成交额15.7亿美元。消息面上，公司宣布旗下两款实验性眼科药物Zenkuda及tabirafusp-ted在湿性年龄相关性黄斑变性III期临床试验中均达到主要终点，两项治疗在第一年视力改善方面均实现对阿柏西普的非劣效性，且54%的患者在第一年内维持了六个月的给药间隔。公司计划于第四季度向监管机构提交Zenkuda在五项III期研究中的数据，覆盖湿性黄斑变性、糖尿病视网膜病变及视网膜静脉阻塞后黄斑水肿等适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Kodiak Sciences盘中大涨，眼科新药III期试验成功","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165743631","title":"Kodiak Sciences第二季度净亏损6564.3万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165743631","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165743631?lang=zh_cn&edition=full","pubTime":"2026-08-14 04:14","pubTimestamp":1786652083,"startTime":"0","endTime":"0","summary":"8月13日，Kodiak Sciences Inc. 公布第二季度财报，营收表现不佳，净亏损达到6564.3万美元。与此同时，该公司每股基本收益为-1.05美元，这一数据低于市场预期。财报显示，公司在本季度面临不小的财务压力，投资者需密切关注其后续业绩走向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124423666","title":"Kodiak Sciences宣布：全球III期ALTO试验启动，Ksi-501首例糖尿病黄斑水肿患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1124423666","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124423666?lang=zh_cn&edition=full","pubTime":"2026-08-11 04:45","pubTimestamp":1786394724,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc.今日正式对外宣告，其全球范围的III期ALTO临床试验已成功招募首例患者。此项研究旨在评估Ksi-501在糖尿病黄斑水肿患者群体中的疗效与安全性。这一里程碑式的进展，标志着针对这一常见致盲性眼病的潜在治疗手段，迈入了关键性的验证阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KOD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146556468","title":"Kodiak Sciences完成首项三期PEAK队列入组；顶线数据预计2026年12月公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146556468","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146556468?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:01","pubTimestamp":1786014085,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc.（KOD）——这家生物科技公司已顺利完成其首项三期PEAK临床试验的受试者入组工作。根据公司公告，顶线数据预计将在2026年12月对外披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KOD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kodiak.com;ir.kodiak.com","stockEarnings":[{"period":"1week","weight":0.0219},{"period":"1month","weight":1.7801},{"period":"3month","weight":1.1162},{"period":"6month","weight":0.9543},{"period":"1year","weight":4.1216},{"period":"ytd","weight":2.1341}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kodiak Sciences Inc.于2009年6月22日以Oligasis LLC的名义成立为有限责任公司。2015年9月8日更名并在特拉华州注册成立公司。该公司是一家临床阶段的生物制药公司，专门研究治疗慢性高流行性视网膜疾病的新疗法。Kodiak Sciences Inc.最先进的候选产品是KSI-301，这是一种使用公司抗体生物聚合物偶联平台（ABC Platform）构建的生物疗法，旨在维持眼组织中有效且有效的药物水平。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.076525},{"month":2,"riseRate":0.5,"avgChangeRate":-0.093763},{"month":3,"riseRate":0.125,"avgChangeRate":-0.076889},{"month":4,"riseRate":0.625,"avgChangeRate":0.017136},{"month":5,"riseRate":0.5,"avgChangeRate":0.047406},{"month":6,"riseRate":0.75,"avgChangeRate":0.031274},{"month":7,"riseRate":0.625,"avgChangeRate":0.076709},{"month":8,"riseRate":0.5,"avgChangeRate":0.003695},{"month":9,"riseRate":0.75,"avgChangeRate":0.304064},{"month":10,"riseRate":0.625,"avgChangeRate":0.176819},{"month":11,"riseRate":0.75,"avgChangeRate":0.296496},{"month":12,"riseRate":0.625,"avgChangeRate":0.266402}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kodiak Sciences Inc.(KOD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kodiak Sciences Inc.(KOD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}